The Motley Fool
13 Sept 2026, 21:24 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
XLV has outperformed IXJ in both one-year and five-year total returns. — Historical outperformance of the domestic-focused ETF over the global one suggests a recent premium on US healthcare assets.
+0.20XLV maintains a significantly lower expense ratio of 0.08% compared to IXJ's 0.38%. — Lower cost structures generally increase long-term net returns for investors, making XLV more attractive on a cost-basis.
+0.10XLV is more concentrated, with its top three holdings (Eli Lilly, J&J, AbbVie) making up roughly 33% of the portfolio versus 22% for IXJ. — Higher concentration increases the fund's sensitivity to the price movements of a few specific mega-cap pharma companies.
+0.05Which stocks this story touches
Continue reading
5 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
8h ago
